# Why Weight Loss on a GLP-1 May Be Slower Than Expected

Why GLP-1 weight loss can look slow in the first months, what the Wegovy and Zepbound trials actually measured, and what to ask at a follow-up.

Canonical HTML: [Why Weight Loss on a GLP-1 May Be Slower Than Expected](https://joinelovi.com/blog/why-weight-loss-on-a-glp-1-may-be-slower-than-expected)

Prepared by [Ēlovi Editorial](https://joinelovi.com/blog/authors/elovi-editorial).
Published: 2026-10-06T02:40:00.000Z. Updated: 2026-10-06T02:40:00.000Z.
Prepared by Ēlovi Editorial with AI assistance. Sources checked: 2026-10-06. Reviewed by the Ēlovi editorial team, which includes licensed clinicians.
[Editorial process](https://joinelovi.com/blog/editorial-policy).

## The short answer

Slower-than-expected weight loss on a GLP-1 is common, and the trials explain part of why. The Wegovy and Zepbound studies measured results at 68 and 72 weeks, after a dose-escalation period of up to 20 weeks, and even then individual results varied widely: in the Wegovy trial of people without diabetes, 83.5% lost at least 5% of their body weight and 47.9% lost at least 15%, so roughly half did not reach 15%. Slow progress is a question for your prescriber, not a verdict, and it is not a reason to change your own dose.

## Which symptoms mean you should call a clinician instead of waiting?

Slow weight loss is not an emergency. Some symptoms that can appear on a GLP-1 are, and they matter more than your pace.

- **Severe stomach pain, especially pain that spreads to your back, with or without nausea or vomiting.** The Wegovy label describes these as the symptoms of pancreatitis and tells patients to stop the medicine promptly and contact their physician if pancreatitis is suspected. [1](https://www.novo-pi.com/wegovy.pdf)
- **Vomiting, diarrhea, or nausea that leaves you dehydrated.** Both labels report acute kidney injury, some cases needing dialysis, mostly in people whose stomach side effects led to dehydration. [1](https://www.novo-pi.com/wegovy.pdf) [2](https://pi.lilly.com/us/zepbound-uspi.pdf)
- **Pain in the upper abdomen, fever, yellowing of the skin or eyes, or clay-colored stools.** The Wegovy Medication Guide lists these among the signs of gallbladder problems, and the label asks patients to contact their provider if gallbladder disease is suspected. [1](https://www.novo-pi.com/wegovy.pdf)

Contact your prescriber the same day for any of these, or seek emergency care if symptoms are severe. If you cannot eat or keep fluids down, that is also a reason to call, even if the scale is the thing you were worried about. Nothing here tells you your own symptoms are harmless; only a clinician who knows your history can assess them.

## How slow is "slower than expected"?

There is no single expected pace to be slower than. The pivotal trials for the two products compared here, Wegovy and Zepbound, each ran well over a year:

- The Wegovy trials assessed weight after **68 weeks**. [1](https://www.novo-pi.com/wegovy.pdf)
- The Zepbound trials assessed weight after **72 weeks**, of which at least 52 weeks were at the maintenance dose. [2](https://pi.lilly.com/us/zepbound-uspi.pdf)

In the Zepbound trials, dose escalation lasted up to 20 weeks before the maintenance period began. [2](https://pi.lilly.com/us/zepbound-uspi.pdf) A medicine that is still being stepped up by your prescriber is not yet at the dose the headline numbers describe. How and when your own dose changes is your prescriber's decision; your product's instructions and your prescriber, not this page, set the schedule.

The headline figures also came from people who were doing more than taking a medicine. In both sets of trials, participants received instruction for a reduced-calorie diet (about 500 kcal/day below need) and counseling to reach at least 150 minutes of physical activity a week. [1](https://www.novo-pi.com/wegovy.pdf) [2](https://pi.lilly.com/us/zepbound-uspi.pdf) That is a trial design, not a rule for you. It does show that the published results describe medicine plus a lifestyle program. NIDDK says the same thing in plain words: these medicines "don't replace physical activity or healthy eating habits," and work best combined with a lifestyle program. [3](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity)

## How much do results vary between people on the same medicine?

A great deal. This table is our own arrangement of figures printed in the two labels, for adults in the trials without type 2 diabetes. The "did not reach" column is simple subtraction from the label's percentages. It is a rough guide, because the labels also report that some participants' weights were missing at the final visit and were estimated.

| Measure at the end of the trial | Wegovy (68 weeks) [1](https://www.novo-pi.com/wegovy.pdf) | Zepbound (72 weeks, range across the three studied maintenance arms) [2](https://pi.lilly.com/us/zepbound-uspi.pdf) |
|---|---|---|
| Average weight change, medicine group | −14.9% | −15.0% to −20.9% |
| Average weight change, placebo group | −2.4% | −3.1% |
| Reached at least 5% loss | 83.5% | 85.1% to 90.9% |
| Reached at least 10% loss | 66.1% | 68.5% to 83.5% |
| Reached at least 15% loss | 47.9% | 48.0% to 70.6% |
| Did not reach 5% loss | about 16.5% | about 9.1% to 14.9% |
| Did not reach 15% loss | about 52.1% | about 29.4% to 52.0% |

Read it this way: on both medicines, most people in the trials lost at least 5%, and a meaningful minority did not. A person who is losing slowly is inside the range the trials found. That does not mean slow progress is fine for you, and it does not mean it is a problem. It means the question belongs in a conversation with the person prescribing.

## Do people with type 2 diabetes lose less?

On average, yes, in the same trials. In the Wegovy study of people with type 2 diabetes, the average loss was 9.6% against 3.4% on placebo, compared with 14.9% against 2.4% in the study of people without diabetes. [1](https://www.novo-pi.com/wegovy.pdf) In the Zepbound study of people with type 2 diabetes, averages ranged from 12.8% to 14.7%, below the 15.0% to 20.9% seen in the study without diabetes. [2](https://pi.lilly.com/us/zepbound-uspi.pdf)

If you have diabetes, a plan built from the figures for people without it will look slower than it is. Ask your prescriber which trial population looks most like you, and remember that a population average is still not a prediction for one person.

## What does NIDDK say about slow progress?

NIDDK says that, on average, after one year adults who take these medicines as part of a lifestyle program lose 3% to 12% more of their starting body weight than people in a lifestyle program without medication. [3](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) Results vary by medication and by person. [3](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity)

NIDDK also describes a checkpoint: if you have not lost at least 5% of your starting weight after 12 weeks on the full dose, your health care professional will probably advise you to stop. [3](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) That sentence describes what a prescriber may do, not a deadline you should apply to yourself. Whether you have been on the full dose for 12 weeks, whether your results are measured fairly, and whether something else is going on are exactly what the prescriber works out. If you are under that mark, the right step is to ask, not to stop or to change anything alone.

## What should you not do when progress feels slow?

- **Do not change your own dose or timing.** Dose changes belong to your prescriber and your product's instructions.
- **Do not add products to speed things up.** Ask your prescriber before adding any supplement or nonprescription product.
- **Do not assume compounded and approved products behave the same.** The figures above come from approved, branded products. They do not transfer to a compounded preparation, which is not FDA-approved. Our [guide to compounded and brand-name GLP-1s](https://joinelovi.com/blog/compounded-vs-brand-name-glp-1) explains the difference.
- **Do not treat a stall as a personal failure.** Weight is a clinical measure here, not a moral one.

## What can you track so a follow-up is more useful?

A single number on a single day tells your prescriber little. These notes help them see a pattern and rule things out. They are a checklist for the conversation, not instructions for self-treatment.

| Bring | Why it helps |
|---|---|
| Your dose history, as your prescriber gave it, with dates | Shows how long you have been on your current dose |
| Weight measurements, as your care team asked you to take them, with dates | A trend is more informative than one reading |
| What you are eating most days, honestly, including appetite changes | Shows whether appetite has changed and whether you are eating enough |
| Side effects and when they happen | Stomach side effects can limit eating, and some need care now |
| Sleep, stress, and recent illness or surgery | Other things in your life can shape results |
| All medicines and supplements, including any new prescriptions | Some medicines affect weight, and your prescriber needs the full list |
| Muscle and activity notes | Our article on [GLP-1s and muscle loss](https://joinelovi.com/blog/glp-1s-and-muscle-loss-what-the-evidence-shows) covers why strength matters |

## What should you ask your prescriber?

- What dose am I on, and when did I reach it?
- What result would we expect to see by the next visit, and what would change the plan?
- Could another medicine, a health condition, or a recent change be involved?
- Is the amount I am eating enough?
- How and when will we review whether this treatment is working for me?
- If it is not, what are the options, and what do they cost?

Our guide to [preparing for your follow-up appointment](https://joinelovi.com/blog/preparing-for-your-glp-1-follow-up-appointment) walks through the visit, and [what a GLP-1 care plan should include](https://joinelovi.com/blog/what-should-be-included-in-a-glp-1-care-plan) lists what you can expect from your care team between visits. If you are still in your first months, our [first 90 days planner](https://joinelovi.com/blog/starting-glp-1) lays out the questions in order.

## Common questions

### Is slow weight loss on a GLP-1 a sign the medicine is not working?

Not by itself. The trials show wide variation, and a slow start can fall inside it. Only your prescriber, with your dose history and measurements, can say whether it is working for you.

### Will weight loss speed up once I reach my full dose?

The evidence does not settle this for any one person. The trial results describe averages measured after months at maintenance dose, and individual paths differ. Ask your prescriber what they expect for you.

### Can I ask for a higher dose?

You can ask your prescriber about your plan. Do not raise your dose yourself. Any change is a prescribing decision.

### What happens to weight if I stop?

NIDDK says you probably will regain some weight after you stop a weight-management medication, and that healthy eating habits and more physical activity may help you regain less. [3](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) Talk with your prescriber before you stop anything.

## References

1. [Wegovy Prescribing Information and Medication Guide](https://www.novo-pi.com/wegovy.pdf) — Novo Nordisk
2. [Zepbound Prescribing Information](https://pi.lilly.com/us/zepbound-uspi.pdf) — Eli Lilly and Company
3. [Prescription Medications to Treat Overweight & Obesity](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity) — National Institute of Diabetes and Digestive and Kidney Diseases

For general education; this does not replace medical advice or an individual evaluation. Talk to your clinician before starting, changing, or stopping treatment. Compounded medications are not FDA-approved.